Sophiris Bio Inc. (NASDAQ:SPHS) fell 4.8% during mid-day trading on Friday . The stock traded as low as $2.26 and last traded at $2.37, with a volume of 1,062,277 shares trading hands. The stock had previously closed at $2.49.

Several research firms recently issued reports on SPHS. Echelon Wealth Partners reissued a “buy” rating and set a $5.00 price objective on shares of Sophiris Bio in a research note on Friday, June 10th. Maxim Group restated a “buy” rating and set a $4.00 price target on shares of Sophiris Bio in a research report on Friday, June 10th.

The stock’s market cap is $50.79 million. The firm’s 50 day moving average price is $1.57 and its 200-day moving average price is $1.60.

Sophiris Bio (NASDAQ:SPHS) last issued its earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.06. Analysts forecast that Sophiris Bio Inc. will post ($0.73) EPS for the current fiscal year.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.